AIDOT Co., Ltd. announced on August 22 that it has obtained a patent in Korea for its “Endoscopic Image Lesion Diagnosis System” related to its flagship product, GIGA dot AI. This patent registration is seen as proof of AIDOT’s superiority in the field of AI-assisted gastric cancer image detection and diagnosis systems. GIGA dot AI, an AI solution that received Class III medical device approval from the Korean Ministry of Food and Drug Safety last year, receives real-time input from gastroscopy images and rapidly analyzes and displays the location and severity of lesions on the screen, providing actionable information. This software is the world’s first to mark the location of gastric lesions across six severity categories (AGC, EGC(SM), EGC(M), HGD, LGD, Normal) with high accuracy. Furthermore, to facilitate overseas expansion, the company has been conducting additional clinical studies in cooperation with hospitals in various countries, and overseas demonstration projects are expected to begin soon as contracts have been signed. The patent focuses on how the AI processes and presents information on automatically classified lesions in a manner easily comprehensible to medical staff, and it also strengthens the protections for systems that can automatically determine whether images are from endoscopy inside the body. AIDOT CEO Jaehoon Jung stated, “With GIGA dot AI, we expect to enhance opportunities for early detection and treatment of gastric cancer while reducing costs. By leveraging AI, we will further increase diagnostic accuracy for doctors, reduce their fatigue, and ultimately improve the efficiency of medical resources.” 

Korea Economic TV / 2024.08.26 / Deputy Director Yang Jae-jun